In order to break through the limitation of scarce and lack of persistence of autologous T cells, the advantage of using donor derived T cells lies in: combining CAR-T to kill tumor cells and the GVL effect of donors, easy collection, and good persistence; But it is necessary to choose HLA type matching donors as much as possible to reduce GVHD and post transplant rejection.

At the same time, pharmaceutical companies need to conduct HLA typing when developing new cancer drugs and vaccines, search for specific types of drug immunotherapy, and confirm personalized and specific immunotherapy to avoid ineffective use of broad-spectrum anti-tumor drugs. When developing vaccines, HLA specific genotype peptides such as HLA-A * 0201 are often used to improve binding efficiency and therapeutic effectiveness. Weihe Biotechnology can provide multiple methodological testing services such as NGS, SBT, qPCR, SSP, etc., fully realizing the multi-dimensional legal, multi resolution requirements, diversified scientific research and clinical typing requirements of HLA.

Testing items